Fosfomycin IV

Fosfomycin IV

Form: Intravenous (IV)

Strength: 2 g, 4g per vial

Reference Brands: Zyflo(US)

Category: Antibiotics

Fosfomycin IV is approved in the EU and US for complicated urinary tract infections and systemic bacterial infections. In the EU, brands like Fosfomycin are regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing standards. In the US, FDA approval relies on extensive clinical data; generics are available. Both regions require detailed dossiers, including clinical trial results, manufacturing practices, and pharmacovigilance plans for approval and ongoing safety. To navigate complex regulatory requirements, optimize dossier submission, and ensure compliance, visit PharmaTradz. We facilitate seamless market access for fosfomycin IV, ensuring adherence to European and US standards for safe, effective antimicrobial therapy.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Colistin (Polymyxin E) Inhalation Solution (Nebulizer)

Strength: 75 mg/2 mL

Form: Inhalation Solution (Nebulizer)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Colistin (Polymyxin E)

Strength: 150 mg/5 mL, 300 mg/5 mL, 1.5 million IU/vial

Form: Injectable (IV/IM/SC)

Reference Brands: Coly-Mycin M(US)

View Details Get Enquiry
Fosfomycin Oral Sachets or Powder for Suspension

Strength: 3g in a sachet

Form: Oral Sachets or Powder for Suspension

Reference Brands: Zyflo(US)

View Details Get Enquiry
Teicoplanin Injectable (IV/IM)

Strength: 200 mg/100 mL, 400 mg/200 mL, 400 mg/100 mL

Form: Injectable (IV/IM)

Reference Brands: Targocid, Tolocin(US & EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.